급성 림프성 백혈병용 CAR T 세포치료 시장 - 세계 및 지역별 분석 : 유래 유형별, 표적 유형별, 지역별 - 분석과 예측(2025-2035년)

Market Lifecycle Stage

The global CAR T-cell therapy for acute lymphoblastic leukemia market is currently in the growth stage of its lifecycle. Following the approval of pioneering therapies such as Kymriah and the successful demonstration of their efficacy in treating relapsed and refractory ALL, the market has seen a significant increase in adoption. This stage is characterized by expanding clinical evidence, increasing patient access, and growing investment in research and development. Furthermore, with regulatory approvals and new therapies entering the market, the industry is poised for further expansion. However, challenges such as high treatment costs, manufacturing complexities, and the need for long-term safety data remain. Despite these obstacles, the market is experiencing robust growth driven by innovations in therapy, strategic partnerships, and the ongoing development of next-generation CAR T-cell therapies.

Impact

• Increasing demand for CAR T-cell therapy for acute lymphoblastic leukemia therapies is anticipated to support the growth of the global CAR T-cell therapy for acute lymphoblastic leukemia market during the forecast period 2025-2035.
• The global CAR T-cell therapy for acute lymphoblastic leukemia market is expected to grow at a significant rate due to advancements in diagnostic technologies, the development of innovative therapies, and increasing awareness among patients and healthcare providers.

Market Segmentation:

Segmentation 1: by Source Type

• Autologous
• Allogeneic

Segmentation 2: by Target Type

• CD19
• CD22
• Others

Segmentation 3: by Region

• North America
• Europe
• Asia-Pacific
• Rest-of-the-World

North America is expected to dominate the global CAR T-cell therapy for acute lymphoblastic leukemia market during the forecast period due to its advanced healthcare infrastructure, high prevalence of disease, and increased awareness of the disease. The region also benefits from regulatory advantages and a strong pharmaceutical presence, which accelerates the availability of effective treatments and drives the growth of the global CAR T-cell therapy for acute lymphoblastic leukemia market.

Recent Developments:

• Regulatory Activities: In March 2025, the FDA approved the IND application for CTD402 for treating pediatric and adult patients with relapsed/refractory T-ALL/LBL, which enabled the commencement of a single-arm, open-label phase 1b/2 trial.
• Regulatory Activities: In November 2024, the FDA granted marketing approval for Autolus Therapeutics' CAR-T cell therapy, AUCATZYL, for the treatment of adult patients with r/r B-ALL.

Demand - Drivers and Limitations

The following are the drivers for the global CAR T-cell therapy for acute lymphoblastic leukemia market:

• Rising Prevalence of Acute Lymphoblastic Leukemia
• Advancements in Manufacturing and Process Improvements
• Robust Product Pipeline with Regulatory Approvals Across Geographies

The global CAR T-cell therapy for acute lymphoblastic leukemia market is expected to face some limitations too, due to the following challenges:

• High Treatment Costs

How Can This Report Add Value to an Organization?

Product/Innovation Strategy: Product launches and innovations in the global CAR T-cell therapy for acute lymphoblastic leukemia market are focused on advancing treatment options to improve patient care. These innovations aim to enhance the efficacy of therapies and streamline the detection and management of the disease. Key players in the market, such as Autolus Therapeutics, have been involved in the development of therapies for CAR T-cell therapy for acute lymphoblastic leukemia.

Competitive Strategy: Enterprises led by market leaders in the global CAR T-cell therapy for acute lymphoblastic leukemia market are continuously working on updating their product portfolios with innovative treatments to maintain competitiveness. A detailed competitive benchmarking of the key players in the global CAR T-cell therapy for acute lymphoblastic leukemia market has been conducted, providing insights into how these companies compare in terms of product offerings, market share, and innovation. This benchmarking provides readers with a clear understanding of the market landscape and the positions of the leading players. Additionally, comprehensive competitive strategies, such as partnerships, agreements, and collaborations, will help readers identify untapped revenue opportunities in the market.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and by analyzing company coverage, product portfolio, and market penetration.

The top segment players include CAR T-cell therapy for acute lymphoblastic leukemia therapy providers that capture around 95% of the global CAR T-cell therapy for acute lymphoblastic leukemia market.

Some of the prominent names established in this market are:

• Autolus Therapeutics
• Bioheng Therapeutics
• Cellectis S.A.
• Gilead Sciences
• Novartis AG
• Wugen, Inc.
• OneChain Immunotherapeutics

Table of Contents

Executive Summary

Scope of Study

1. Global CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Market: Market Outlook

• 1.1 Industry Outlook
  • 1.1.1 Market Overview and Ecosystem
  • 1.1.2 Key Trends
  • 1.1.3 Epidemiological Analysis of Acute Lymphoblastic Leukemia
    • 1.1.3.1 By Region
  • 1.1.4 Clinical Trials
    • 1.1.4.1 By Phase
    • 1.1.4.2 By Sponsor Type
  • 1.1.5 Regulatory Landscape / Compliance
    • 1.1.5.1 Legal Requirement and Framework in the U.S.
    • 1.1.5.2 Legal Requirement and Framework in the E.U.
    • 1.1.5.3 Legal Requirement and Framework in Japan
    • 1.1.5.4 Legal Requirement and Framework in Rest-of-the-World
• 1.2 Market Dynamics
  • 1.2.1 Impact Analysis
  • 1.2.2 Market Drivers
  • 1.2.3 Market Restraints
  • 1.2.4 Market Opportunities

2. Global CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Market, By Source Type, $Million, 2023-2035

• 2.1 Autologous
• 2.2 Allogeneic

3. Global CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Market, By Target Type, $Million, 2023-2035

• 3.1 CD-19
• 3.2 CD-22
• 3.3 Others

4. Global CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Market, By Region, $Million, 2023-2035

• 4.1 North America
  • 4.1.1 Key Findings
  • 4.1.2 Market Dynamics
  • 4.1.3 Market Sizing and Forecast
    • 4.1.3.1 U.S. CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Market (by Country)
      • 4.1.3.1.1 U.S.
• 4.2 Europe
  • 4.2.1 Key Findings
  • 4.2.2 Market Dynamics
  • 4.2.3 Market Sizing and Forecast
    • 4.2.3.1 Europe CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Market (by Country)
    • 4.2.3.2 U.K.
    • 4.2.3.3 Germany
    • 4.2.3.4 France
    • 4.2.3.5 Italy
• 4.3 Asia-Pacific
  • 4.3.1 Key Findings
  • 4.3.2 Market Dynamics
  • 4.3.3 Market Sizing and Forecast
    • 4.3.3.1 Asia-Pacific CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Market (by Country)
    • 4.3.3.2 China
    • 4.3.3.3 Japan

5. Global CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Market - Competitive Benchmarking and Company Profiles

• 5.1 Competitive Landscape
  • 5.1.1 Key Strategies and Developments by Company
    • 5.1.1.1 Funding Activities
    • 5.1.1.2 Mergers and Acquisitions
    • 5.1.1.3 Regulatory Approvals
    • 5.1.1.4 Partnerships, Collaborations and Business Expansions
  • 5.1.2 Key Developments Analysis
• 5.2 Company Profiles
  • 5.2.1 Novartis AG
    • 5.2.1.1 Company Overview
    • 5.2.1.2 Product Portfolio
    • 5.2.1.3 Target Customers/End Users
    • 5.2.1.4 Analyst View
  • 5.2.2 Autolus Therapeutics
    • 5.2.2.1 Company Overview
    • 5.2.2.2 Product Portfolio
    • 5.2.2.3 Target Customers/End Users
    • 5.2.2.4 Analyst View
  • 5.2.3 Gilead Sciences
    • 5.2.3.1 Company Overview
    • 5.2.3.2 Product Portfolio
    • 5.2.3.3 Target Customers/End Users
    • 5.2.3.4 Analyst View
  • 5.2.4 OneChain Immunotherapeutics
    • 5.2.4.1 Company Overview
    • 5.2.4.2 Product Portfolio
    • 5.2.4.3 Target Customers/End Users
    • 5.2.4.4 Analyst View
  • 5.2.5 Cellectis S.A.
    • 5.2.5.1 Company Overview
    • 5.2.5.2 Product Portfolio
    • 5.2.5.3 Target Customers/End Users
    • 5.2.5.4 Analyst View
  • 5.2.6 Wugen, Inc.
    • 5.2.6.1 Company Overview
    • 5.2.6.2 Product Portfolio
    • 5.2.6.3 Target Customers/End Users
    • 5.2.6.4 Analyst View
  • 5.2.7 Bioheng Therapeutics
    • 5.2.7.1 Company Overview
    • 5.2.7.2 Product Portfolio
    • 5.2.7.3 Target Customers/End Users
    • 5.2.7.4 Analyst View

6. Research Methodology